gc4711
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2019 (NCT03762031)
Timeline
Indications
Mechanism of action
- Superoxide dismutaseSupplementation
SOD1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04698915 | Phase 2 | May 7, 2021 | Galera Therapeutics, University of California, San Francisco |
| NCT04476797 | Phase 1/Phase 2 (Phase 2) | Oct 18, 2020 | Galera Therapeutics, University of California, San Francisco |
| NCT03762031 | Phase 1 | Apr 30, 2019 | Galera Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galera Therapeutics | For profit | 3 | 3 | 2 | 2019 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1